Medication info

Daploglisin Duo Extended-Release Tablets 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
PharmGen Science Co., Ltd.
Appearance
Yellow, biconvex, oval extended-release film-coated tablet
Packaging
30 tablets/box [6 tablets/PTP*5], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202300149 · Approved 2023.01.06

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medication should provide the patient’s current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Since changes may cause changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Ingredients

Manufacturer
PharmGen Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood glucose control
  • cardiovascular diseases
  • cardiovascular risk factors
View approved original text

This medication contains dapagliflozin and metformin to assist patients with type 2 diabetes in controlling their blood sugar. It is particularly effective for those who also engage in dietary management and exercise. Additionally, it is used for type 2 diabetes patients who have cardiovascular diseases or risk factors and are not well-controlled. This medication may help with both blood sugar control and cardiovascular health management; therefore, it should be used safely under the guidance of a specialist.

How to take

Adult dose

The dose of this medication should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medication should provide the patient’s current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Since changes may cause changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Precautions

This medication is used for diabetes treatment and contains metformin and dapagliflozin. It should not be used in patients with poor kidney function, severe infections, cardiovascular issues, or liver dysfunction. Pregnant or breastfeeding women should not take this medication. This medication can rarely cause a serious metabolic disorder called lactic acidosis, so immediate consultation with a doctor is necessary if symptoms occur. Furthermore, caution is required when taking this medication in combination with insulin or sulfonylureas due to the increased risk of hypoglycemia. Patients with decreased fluid volume or low blood pressure, elderly patients, or patients with reduced kidney function require careful assessment and continuous monitoring before taking this medication. During treatment, genital infections or urinary tract infections may occur, and immediate medical attention should be sought if symptoms arise. This medication can lower vitamin B12 levels, so regular blood tests may be needed for long-term use. In cases of overdose, appropriate emergency treatment is required, and some components may be removed through dialysis. Dizziness may occur while driving or operating machinery, so caution should be exercised. This medication must be kept out of reach of children and stored in its original container.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis and related genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
  • diabetic ketoacidosis
Show 84 more
  • dizziness
  • constipation
  • dry mouth
  • lumbago
  • dysuria
  • polyuria
  • nocturia
  • pruritus of the vulva
  • pruritus of the genitals
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fractures
  • gastrointestinal stromal tumors
  • lung malignancies
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • dental pain
  • headache
  • facial paralysis
  • peripheral neuropathy
  • altered sensation
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • chondromalacia
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. The recommended storage temperature is between 1°C and 30°C at room temperature to maintain the effectiveness of the medication for a long time.

Appearance and packaging

Appearance

Yellow, biconvex, oval extended-release film-coated tablet

Package unit

30 tablets/box [6 tablets/PTP*5], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.